title: Adoptive cellular therapy: a race to the finish line.
abstract: Adoptive T cell transfer for cancer, chronic infection, and autoimmunity is an emerging field that shows promise in recent trials. Using the principles of synthetic biology, advances in cell culture and genetic engineering have made it possible to generate human T cells that display desired specificities and enhanced functionalities compared with the natural immune system. The prospects for widespread availability of engineered T cells have changed dramatically, given the recent entry of the pharmaceutical industry to this arena. Here, we discuss some of the challenges--such as regulatory, cost, and manufacturing--and opportunities, including personalized gene-modified T cells, that face the field of adoptive cellular therapy.
authors: Center for Cellular Immunotherapies and the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA. cjune@exchange.upenn.edu sriddell@fredhutch.org t.schumacher@nki.nl.
authors: Carl H
authors: CH
authors: June
authors: Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA. cjune@exchange.upenn.edu sriddell@fredhutch.org t.schumacher@nki.nl.
authors: Stanley R
authors: SR
authors: Riddell
authors: Division of Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands. cjune@exchange.upenn.edu sriddell@fredhutch.org t.schumacher@nki.nl.
authors: Ton N
authors: TN
authors: Schumacher
mesh_terms: D019264:Adoptive Transfer / Q000009:adverse effects; D005818:Genetic Engineering; D006801:Humans; D013601:T-Lymphocytes / Q000276:immunology*